FINAL DIAGNOSIS: m ‘ ems)
: . T TAL ‘n-IYROIDEGTO z - _
”RT 1 Wmiﬁu morn OARcmouiA. ENOAPSULATEO FOLLICULAR VARIANT (3.: cu) LOCATED IN THE
LEFT LOSE. comm-:0 TO mom: N0 TUMOR CAPSULE INVASION. .
no ANGIOLYMPHATIC INVASION OR EXTRATHYROioAL EXTENSION.
RESECTION mom FREE OF TUMOR. , ,
on: LEFT PERITHYROIDAL LYMPH NODE FREE OF TUMOR (on a. /&A 0 :3
PATHOLOOIO STAGE: pT2 no. ‘ ‘
MODULAR mom HYPERPLASIA. 6 WI [011,] [[147 ﬁlm W

PART 2: LYMPH NOOEs, CENTRAL COMPARTMENT. DISSECTION - VII/MW 5’3 90/}
IL SEVEN LYMPH Nooss FREE OF TUMOR (M).
3. 1155115 EN11RELT suaun'TEO FOR MICROSGOPIG EVALUATION. 51‘1"; ; l 1 II, pp; 073 . .7

rnppw

CASE SYNOPSIS: »
SYNOPTIC DATA - PRIWY THYROID TUMOR!
SPECIMEN TYPE: TOM Thyroidoctomv
TUMOR SITE: LeI'lLobo ,0/7/0
TUMOR FOCAUTY: Unilocal
NMOR SIZE (largest nodule): (Smallest Dimension: 3.6 cm lated fall! I“ variant
HISTOLOGIC TYPE“: Pap aiy carcinma. enumu cu .
PRIMARY TUMOR (pT): prz ‘ I 06 '9. gum/z» VM ,1» 1'“ -

REGIONAL LYMPH MODES (9N): pNO
Number of regional lymph nodes examined: 8
Number of regional lymph nodes involved: 0

DISTANT METASTASIS (pill): Not applicabl-

EXTRATHYROIDAL EXTENSION: Nat identiﬁed

MARGINS: . Margins uninvolved by carcinoma

LYMPH-VASCULAR INVASION: Not Identiﬁed . .

ADDITIONAL PATHOLOGIC FINDINGS: Omar. nodular thyroid hyperplnla
Addendum

MOLECULAR ANATOMIC PATHOLOGY TESTING:
Block 13: I

A. BRAF mutation lDENTIFIED (p.V600E, mmraﬁ

B. Mutations in N A561,HRASG1. KRA512/18 and RET/PT 1 R
NOT identified. . c and Emma rearrangemanh

NOTE: . -
, . l
Nucleic acids mm "karma In tho amount ﬂrfﬁcllnt for telling.

BACKGI}OUND:r , '

l

Mutallons in either F or RAS genes or RET/PTC rearrangement. are found in more than 70% of 'l '
$4 I. _ mod
(1}. BRAF VSOOE .ITQQA) mtlIa‘bOﬂ hag been auoclalod wilh more aggressive behavior ofpapliiarypcaae‘ﬁmma (2.'3fa:$l?:ma
aoeociatlon belwoen-BRAF V6006 mutation and features of tumor aggressiveness have also been observed In papillary
microcamhomaa 'h Mutations In the RAS genes or PAXM’PARg rearrangement occur in ~70% of Ioliicular thyroid carcinoma.
and wrth lower cy in moocyrchHamrle cell) carcinoma: (5). Regarding the speciﬁcity of lhoso mutations for cancer. BRAF
. nwin tho raid allho mm

have been Iroporlqdmlh a very low frequency in benign Inward lesions (5). RAS mutations occur in maligngg and, baniganMyroiﬁ

tumors. blll'lg fouaqln «060% of follloular and one ' ‘ '
carcinoma: (a) r W plastic carolnornazlr, 30—40% of follicular adenomas and 10-15% oi papillary

iAdpanuagmmmmmmmwmm'Emcm minnow-is, my her-claim
imrrrmmdwwmmm ”d "° °'
, ‘, a msamamummmrpaplmmmmmnnmummaww
3.EilamRolal.HRAF\/800£nmrwmmd - . - ‘ 34379.
‘L x. cub M33394 mwmmmwmwmmarmummmmuam
.eo MJILY: 'Y.Fong?.LiY. Y, W,Zhan.A ‘ I”
gaff???“ .MN “a A‘s .msmglhang mnwnzmndydso‘lmwswwmmuterbnelmluomhighawesm
W1 . mmwsmxa-PPARN in - '
‘lor . J Cﬁn Er mm 88: 2;1&uzr:rlgenwm Ihyroldiumors Evmnoa fwd-ﬁbumm; In

0. Milton; YE Rmawbpmom in the mbcula' a! " — . '
“mm" A . Hu Term, ' 1933337 ﬁle mm In. Lloyd RV., bd. Endocnm Pathology, Drlferanfiai Dogma: and

 

ro’UTATIONAL ANALYSIS:
MW ‘ A ’ ' , “manual . . .
uﬂumorcoiislnl on form gummmwwmmam. Smmmrhihemirmwnofstm

t.
on AmnﬁﬁmllqgoﬂhoKRﬂgemwasusedIoWWWWWNRNAWWNONWMpmmM
spedmon. DNAorRNA, WMMEMNMuMnMMMQWWanuﬁcarbnarascydooorearﬂorwas
0mm mgmmmrmbanavab. Thollmifoldelomon' ismmmiy 10-20%olailoluwﬂhmmmnmminlhebock9mundolmnnal

UUID:526938F6-37F3-4B78-AFE5-301AED24EADA
TCGA-BJ-A409-91A-PR Redacll'lted

 

II
n

 
 

‘i'IUl-Unrrl

      
 
 
 
 
 

. .. z I Site
I Izi! ,1 s 'r ... ﬂy Sag-galley
1!

.lv‘ 1 . _Prior Malignancy Halon; '

l w;... .4

«\‘7

  

l'._ b ”g I ll ‘- ‘Cau
Reviewer lniliais

 
 

